Kurt Blasena joins Digital Diagnostics as Chief Commercial Officer
The company created this new role as they see continued growth and room for more expansion.
(Image credit: AdobeStock/Shuo)
Kurt Blasena joins Digital Diagnostics as Chief Commercial Officer, a the newly created role within the company’s executive leadership team.
In the news release1, Blasena shares his enthusiasm for the company and the future of their AI tools. He said, "I'm excited to join Digital Diagnostics at this pivotal time of growth in the healthcare AI industry. What attracted me to the company is its focus on providing access to equitable care, fostering strong corporate culture, and prioritizing bringing AI to market in a way that positively impacts patient outcomes and the healthcare organizations they serve. Digital Diagnostics has a proven track record in the diabetes market and a strong vision for what is to come in the industry."
The company shared some background and choice welcome Blasena into the company, noting that Blasena is a seasoned leader who excels at attracting and developing talented teams with a history of delivering results and scaling revenue from a start-up stage to +$200 million. They went on to say that Blasena has a passion for increasing access and quality in healthcare and has extensive experience in leading commercial organizations focused on digital health, artificial intelligence, and SaaS. Most recently, Blasena served as Chief Revenue Officer of Viz.ai leading highly effective commercial teams to scale the business.1
Digital Diagnostics' CEO, John Bertrand, shared his thoughts on Blasena joining the team in the press release1, saying, "I am pleased to welcome Kurt to Digital Diagnostics. In this newly formed role, his more than 20 years of healthtech experience will help propel and strengthen our position in the market. His expertise, creativity, and leadership in digital health will continue to drive the work we are doing to transform the affordability, accessibility, equity, and quality of patient care. I look forward to working alongside him as we continue advancing AI in healthcare."
"Kurt brings extensive knowledge and leadership to the company and I'm confident he will help launch Digital Diagnostics into the next frontier of growth," remarked Sarah Tibesar, Chief Operating Officer, who was promoted mid-2023 to lead the company's strategic operations. "Our foundational principles of groundbreaking innovation rooted in health equity and access to care have been proven in the past several years, and now is an excellent time for someone of Kurt's caliber to join Digital Diagnostics, bringing new perspective that will continue to enhance the Company's commercial position in the market."1
Digital Diagnostics has seen sizable growth recent years including a $75M Series B funding round. The company has also gone through a global expansion and commercialization in the Kingdom of Saudi Arabia, obtaining a national rate for reimbursement of its flagship medical device. The have contributed to the larger research on AI in the medical space by publishing the first randomized clinical trial of autonomous AI proving better patient outcomes and productivity, and publishing several peer reviewed publications and real-world evidence case studies.1
